medigraphic.com
ISSN 0016-3813 (Print)

2017, Number 1

<< Back Next >>

Gac Med Mex 2017; 153 (1)

Herpes zoster and post-herpetic neuralgia in the elderly: Particularities in prevention, diagnosis, and treatment

García-González AI, Rosas-Carrasco O

Language: Spanish
References: 65
Page: 92-101
PDF size: 102.42 Kb.


ABSTRACT

Herpes zoster (HZ) results from the reactivation of the varicella zoster virus latent in the sensory ganglia when cell-mediated immunity is altered. It is a frequent condition in older adults, leading to undesirable adverse outcomes. Aging is its main risk factor and the elderly may have different clinical presentations: zoster sine herpete, and a higher incidence of post-herpetic neuralgia (15%) and ophthalmic herpes (7%). Both HZ and post-herpetic neuralgia may impact the quality of life, functional status, mental health, and social interaction in older adults. Clinical trials have demonstrated that the vaccine decreases the incidence of HZ and post-herpetic neuralgia by up to 51% and 67%, respectively. When treating older adults with multi-morbidity, practitioners should consider starting low-dose drugs so they can look for potential drug-drug and drug-disease interactions. The aim of this article was to review the particularities of the risk factors, clinical presentation, complications, and treatment of HZ and post-herpetic neuralgia.


REFERENCES

  1. Gnann JW, Whitley RJ. Herpes zoster. N Engl J Med. 2002;347:340-6.

  2. Schmader K, Gnann JW Jr, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis. 2008;197(Suppl 2):S207-15.

  3. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004;4:26-33.

  4. Franco E, Gabutti G, Bonanni P, et al. [Herpes Zoster and its prevention in Italy. Scientific consensus statement]. Ig Sanita Pubbl. 2014;70:111-27.

  5. Conde-Glez C, Lazcano-Ponce E, Rojas R, et al. Seroprevalences of varicella-zoster virus, herpes simplex virus and cytomegalovirus in a cross-sectional study in Mexico. Vaccine. 2013;31:5067-74.

  6. Forbes HJ, Bhaskaran K, Thomas SL, et al. Quantification of risk factors for herpes zoster: population based case-control study. BMJ. 2014; 348:g2911.

  7. Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007;25:8326-37.

  8. Kawai K, Preaud E, Baron-Papillon F, Largeron N, Acosta CJ. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review. Vaccine. 2014;32:1645-53.

  9. Solana R, Tarazona R, Gayoso I, Lesur O, Dupuis G, Fulop T. Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans. Semin Immunol. 2012;24:331-41.

  10. Maue AC, Yager EJ, Swain SL, et al. T-cell immunosenescence: lessons learned from mouse models of aging. Trends Immunol. 2009;30:301-5.

  11. Gershon AA, Gershon MD, Breuer J. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol. 2010;48(Suppl 1):S2-7.

  12. Arvin AM, Moffat JF, Redman R. Varicella zoster virus. Adv Virus Res. 1996;46:263-309.

  13. Iglar K, Kopp A, Glazier RH. Herpes zoster as a marker of underlying malignancy. Open Med. 2013;7:e68-73.

  14. Chen JY, Cheng TJ, Chang CY, et al. Increased incidence of herpes zoster in adult patients with peptic ulcer disease: a population-based cohort study. Int J Epidemiol. 2013;42:1873-81.

  15. Aldaz P, Díaz JA, Loayssa JR, et al. Herpes zoster incidence in diabetic patients. An Sist Sanit Navar. 2013;36:57-62.

  16. Liu B, Heywood AE, Reekie J, et al. Risk factors for herpes zoster in a large cohort of unvaccinated older adults: a prospective cohort study. Epidemiol Infect. 2015;143:2871-81.

  17. Schmader K, George LK, Burchett BM, Pieper CF. Racial and psychosocial risk factors for herpes zoster in the elderly. J Infect Dis. 1998;178(Suppl 1):S67-70.

  18. Oxman MN. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology. 1995;45:S41.

  19. Alonzo-Romero Pareyón L. Herpes zoster. Dermatol Rev Mex. 2011;55: 24-39.

  20. Schmader K, Sloane R, Pieper C, et al. The impact of acute herpes zoster pain and discomfort on fuctional status and quality of life in older adults. Clin J Pain. 2007;23:490-6.

  21. Duracinsky M, Paccalin M, Gavazzi G, et al. ARIZONA study: is the risk of post-herpetic neuralgia and its burden increased in the most elderly patients? BMC Infect Dis. 2014;14:529.

  22. Kost RG, Straus SE. Postherpetic neuralgia: pathogenesis, treatment, and prevention. N Engl J Med. 1996;335:32-42.

  23. Lewis GW. Zoster sine herpete. Br Med J. 1958;2:418-21.

  24. Kennedy PG. Zoster sine herpete: it would be rash to ignore it. Neurology. 2011;76:416-7.

  25. Vena GA, Apruzzi D, Vestita M, Calvario A, Foti C, Cassano N. Zoster ... “almost” ... sine herpete: diagnostic utility of real time-polymerase chain reaction. New Microbiol. 2010;33:409-10.

  26. CDC. Diagnosis & Testing. (Consultado el 23 de marzo de 2015). Disponible en: http://www.cdc.gov/shingles/hcp/diagnosis-testing.html

  27. Yawn B, Wollan P, Saint-Sauver J, Kurland M, Sy LS, Saddier P. Herpes zoster in the community. En: North American Primary Care Research. Group Meeting; 2006.

  28. Volpi A. Severe complications of herpes zoster. Herpes. 2007;14(Suppl 2):35-9.

  29. Heymann AD, Chodick G, Karpati T, et al. Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection. 2008;36:226-30.

  30. Gebo KA, Fleishman JA, Moore RD. Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states. J Acquir Immune Defic Syndr. 2005;40:609-16.

  31. Ragozzino MW, Melton LJ 3rd, Kurland LT, Chu CP, Perry HO. Population- based study of herpes zoster and its sequelae. Medicine. 1982;61:310-6.

  32. Naumann G, Gass JD, Font RL. Histopathology of herpes zoster ophthalmicus. Am J Ophthalmol. 1968;65:533-41.

  33. Shaikh S, Ta CN. Evaluation and management of herpes zoster ophthalmicus. Am Fam Physician. 2002;66:1723-30.

  34. Kanski JJ. Herpes zoster ophthalmicus. En: Kanski JJ, Nischal KK, Milewski SA, editores. Ophthalmology: clinical signs and differential diagnosis. Philadelphia: Mosby; 1999.

  35. Langan SM, Minassian C, Smeeth L, Thomas SL. Risk of stroke following herpes zoster: a self-controlled case-series study. Clin Infect Dis. 2014;58:1497-503.

  36. Gil-Prieto R, San-Martin M, Alvaro-Meca A, Gonzalez-Lopez A, Gil de Miguel A. Herpes zoster hospitalizations of patients with chronic illnesses in Spain 1998-2004. Vacunas. 2011;12:95-101.

  37. Schmader K. Herpes zoster and postherpetic neuralgia in older adults. Clin Geriatr Med. 2007;23:615-32.

  38. Johnson RW, Bouhassira D, Kassianos G, Leplège A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality of life. BMC Med. 2010;8:37.

  39. Bricout H, Perinetti E, Marchettini P, et al. Burden of herpes zoster-associated chronic pain in Italian patients aged 50 years an over (2009-2010): a GP-based prospective cohort study. BMC Infect Dis. 2014;14:637.

  40. Whitley RJ, Volpi A, McKendrick M, Wijck Av, Oaklander AL. Management of herpes zoster and post-herpetic neuralgia now and in the future. J Clin Virol. 2010;48(S1):S20-8.

  41. Ficha técnica Zostavax (consultado el 6 de marzo de 2015). Disponible en: www.cofepris.gob.mx/AS/Documents/RegistroSanitarioMedicamentos/ Vacunas/123M2009.pdf

  42. Oxman MN, Levin MJ, Johnson GR, et al, A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271-84.

  43. Sanford M, Keating GM. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging. 2010;27:159-76.

  44. Chen N, Li Q, Zhang Y, Zhou M, Zhou D, He L. Vaccination for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2011;(3): CD007795.

  45. Cohen JI, Brunell PA, Straus SE, Krause PR. Recent advances in varicella- zoster virus infection. Ann Intern Med. 1999;130:922.

  46. Miller GG, Dummer JS. Herpes simplex and varicella zoster viruses: forgotten but not gone. Am J Transplant. 2007;7:741.

  47. Tyring SK, Beutner KR, Tucker BA, et al. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famcyclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med. 2000;9:863.

  48. Whitley RJ, Weiss H, Gnann JW Jr, et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med. 1996;125:376-83.

  49. Dworkin RH, Schmader KE. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis. 2003;36:877-82.

  50. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44(Suppl 1):S1.

  51. Watson CP, Vernich L, Chipman M, Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology. 1998; 51:1166-71.

  52. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther. 2003;25:81-104.

  53. Drugs.com. Know more be sure. (2000-2017). Dallas, TX, USA. Drug site trust. Disponible en: www.drugs.com/drug_interactions.php

  54. Aciclovir, Famciclovir, Valaciclovir. Ann Abor (M1). Truven Health Analytics; 2015. Disponible en: www.micromedex.com. Subscription required.

  55. Pregabalin (lyrica) for neuropathic pain and epilepsy. Med Lett Drugs Ther. 2005;47:75.

  56. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: doubleblind controlled study of a new treatment method for post-herpetic neuralgia. Pain. 1996;65:39-44.

  57. Hempenstall K, Nurmikko TJ, Johnson RW, A’Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med. 2005:e164.

  58. Derry S, Sven-Rice A, Cole P, et al. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2013;(2):CD007393.

  59. Christo PJ, Hobelmann G, Maine DN. Post-herpetic neuralgia in older adults: evidence-based approaches to clinical management. Drugs Aging. 2007;24:1-19.

  60. Rijsdikj M, van Wijck AJ, Meulenhoff PC, et al. No beneficial effect of intrathecal methylprednisolone acetate in postherpetic neuralgia patients. Eur J Pain. 2013;17:714.

  61. van Wijck AJ, Opstelten W, Moons KG, et al. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial. Lancet. 2006;367:219-24.

  62. Kumar V, Krone K, Mathieu A. Neuraxial and sympathetic blocks in herpes zoster and postherpetic neuralgia: an appraisal of current evidence. Reg Anesth Pain Med. 2004;29:454-61.

  63. Apalla Z, Sotiriou E, Lallas A, et al. Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo- controlled trial. Clin J Pain. 2013;29:857.

  64. Barnard D, Lloyd J, Evans J. Cryoanalgesia in the management of chronic facial pain. J Maxillofac Surg. 1981;9:101.

  65. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44(Suppl 1):S1-26.




2020     |     www.medigraphic.com